ArticleScientific reports2026
Plasma and aqueous humor levels of Maresin-1 in patients with diabetic retinopathy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Maresin-1 in Type 2 Diabetes: A Biomarker Profile in Relation to Diabetic Retinopathy Phenotypes and Proteinuria.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate plasma and aqueous Maresin-1 (MaR1) levels in patients with diabetic retinopathy (DR) and to examine the ability of these levels to distinguish proliferative diabetic retinopathy. The study included three age and gender-matched groups of 25 cataract patients with no diabetes mellitus (DM) or additional disease (C), 25 cataract patients with diabetes and no retinopathy (DM + C), and 25 cataract patients with diabetic proliferative retinopathy (DR + C). All the patients were examined with respect to age, gender, fasting plasma glucose and hemoglobin A1c (HbA1c). Phaco + IOL implantation was applied to all patients in all the groups, and aqueous samples were taken during the operation. The plasma and aqueous MaR1 levels were analyzed using enzyme-linked immunosorbent assays. The diagnostic performance of plasma and aqueous MaR1 levels in distinguishing the DR + C group from the C group was evaluated using receiver operating characteristic (ROC) curve analysis. A statistically significant difference was determined between the groups with respect to fasting plasma glucose, and HbA1c levels (p < 0.0167 for all parameters tested). The plasma MaR1 levels in group DR + C were determined to be statistically significantly lower compared to the C and DM + C groups (p < 0.001). The plasma MaR1 levels in group DM + C were determined to be statistically significantly lower compared to the C group (p < 0.001). The aqueous MaR1 levels in group DR + C were determined to be statistically significantly higher compared to the C and DM + C groups (p < 0.001, p < 0.001, respectively). No statistically significant difference was determined between the DM + C and C groups in respect of the aqueous MaR1 levels (p = 0.590). ROC analysis showed excellent discriminative performance of both plasma and aqueous MaR1 levels in distinguishing the DR + C group from the C group (AUC = 0.968 and 0.974, respectively; both p < 0.001). According to the results of the study, MaR1 levels were significantly lower in plasma and significantly higher in the aqueous humor in the DR + C group. ROC analysis indicated that both plasma and aqueous MaR1 levels showed good discriminative ability in distinguishing the DR + C group from the control group. These findings suggest that alterations in MaR1 levels may be associated with the inflammatory processes involved in diabetic retinopathy and may reflect disease-related biological changes in both systemic circulation and ocular tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.